CuraSen Therapeutics Inc.
https://www.curasen.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CuraSen Therapeutics Inc.
Hopes For A ‘New Era’ In UK Biotech Financing With Pension-Backed Fund
Backed by the UK government and the Phoenix Group, the initial £200m fund is aimed at convincing pension funds to invest in the higher-risk, higher-reward life sciences sector.
US FDA Rejects Melinta Effort To Go Beyond Court Order In FedEx-Driven ANDA Dispute
Court found FDA erred in finding Melinta received notice of Paragraph IV certification for generic Minocin on date specified by Nexus. Agency will not require Nexus to send a new notice or give Melinta heads up of final approval of the ANDA.
Advanced Wound Care: Untapped Opportunities
Mega-deals and innovative technologies have transformed advanced wound care into a robust, high-tech market in the US. While regulatory and reimbursement challenges persist, opportunities in adjacent spaces and under-penetrated OUS markets represent fertile ground for advanced wound care expansion.
Advanced Wound Care – Untapped Opportunities
With worldwide revenues projected to reach $6 billion in 2015, mega-deals and innovative game-changing technologies have transformed the advanced wound care market into a robust, high-tech arena in the US. While regulatory and reimbursement challenges persist, opportunities in adjacent spaces and under-penetrated OUS markets represent fertile ground for advanced wound care expansion.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice